Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Before and after endoscopic images of B-UP (Cohort B, 100 mg)



B-UP Topline Results

Rate of Clinical Remission (% of patients achieving)

- 60% Cohort A (3 of 5 patients)
- 67% Cohort B (4 of 6 patients)
- 75% Cohort C (3 of 4 patients)

(i) #Endoscopy subscore ≤ 1 (% of patients achieving)

- 80% Cohort A (4 of 5 patients)
- 67% Cohort B (4 of 6 patients)
- 75% Cohort C (3 of 4 patients)

(ii) Rectal Bleeding subscore of 0 (% of patients achieving)

- 80% Cohort A (4 of 5 patients)
- 100% Cohort B (6 of 6 patients)
- 100% Cohort C (4 of 4 patients)

(iii) Stool Frequency subscore, improvement or no change from baseline (% of patients achieving)

- 100% Cohort A (5 of 5 patients)
- 100% Cohort B (6 of 6 patients)
- 100% Cohort C (4 of 4 patients)

http://www.ipharminc.com/press-release/2017/7/13/innovation-pharmaceuticals-phase-2-poc-trial-for-inflammatory-bowel-disease-achieves-induction-of-remission-in-a-majority-of-patients-treated-with-brilacidin